复发经典型霍奇金淋巴瘤患者的新型治疗策略。
Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.
机构信息
Department of Lymphoma/Myeloma, M. D. Anderson Cancer Center, Houston, United States.
出版信息
Blood Rev. 2010 Nov;24(6):233-8. doi: 10.1016/j.blre.2010.08.003. Epub 2010 Sep 15.
Abstract
The treatment of patients with relapsed and refractory Hodgkin lymphoma (HL), especially those who relapse after autologous stem cell transplantation, remains challenging. Patients with HL whose disease relapses after stem cell transplantation are rarely cured with current treatment modalities, and have a median survival of less than 3 years. Since no new drugs have been approved by the FDA for HL in more than three decades, there is a clear unmet medical need for drug development for this patient population. New treatment strategies that are based on targeting oncogenic signaling pathways are currently explored. This review will focus on emerging new treatment modalities that are currently under investigation for patients with relapsed classical HL.
摘要
复发和难治性霍奇金淋巴瘤（HL）患者，尤其是那些在自体造血干细胞移植后复发的患者，其治疗仍然具有挑战性。接受干细胞移植后疾病复发的 HL 患者，目前的治疗方法很少能治愈，中位生存期不到 3 年。由于三十多年来 FDA 尚未批准任何新药用于 HL，因此这一患者群体的药物研发存在明显的未满足的医疗需求。目前正在探索基于靶向致癌信号通路的新治疗策略。本文将重点介绍目前正在研究用于复发经典 HL 患者的新兴新治疗方法。
相似文献
1
Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.复发经典型霍奇金淋巴瘤患者的新型治疗策略。
Blood Rev. 2010 Nov;24(6):233-8. doi: 10.1016/j.blre.2010.08.003. Epub 2010 Sep 15.
2
Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.复发经典型霍奇金淋巴瘤患者的新型治疗策略。
Hematology Am Soc Hematol Educ Program. 2009:507-19. doi: 10.1182/asheducation-2009.1.507.
3
Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.在本妥昔单抗时代复发性经典型霍奇金淋巴瘤的治疗
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):151-7. doi: 10.1182/asheducation-2014.1.151. Epub 2014 Nov 18.
4
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.帕博利珠单抗对比本妥昔单抗维布妥昔单抗治疗复发或难治性经典型霍奇金淋巴瘤（KEYNOTE-204）：一项多中心、随机、开放标签、3 期研究的中期分析。
Lancet Oncol. 2021 Apr;22(4):512-524. doi: 10.1016/S1470-2045(21)00005-X. Epub 2021 Mar 12.
5
Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?复发难治性霍奇金淋巴瘤的新兴疗法：在 Brentuximab Vedotin 和 PD-1 抑制之后，接下来会有什么？
Curr Hematol Malig Rep. 2021 Feb;16(1):1-7. doi: 10.1007/s11899-020-00603-3. Epub 2021 Jan 6.
6
Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.使用第二代抗体药物偶联物治疗复发或难治性霍奇金淋巴瘤：聚焦于维布妥昔单抗
BioDrugs. 2014 Jun;28(3):245-51. doi: 10.1007/s40259-013-0077-7.
7
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.本妥昔单抗维泊妥珠单抗作为自体造血干细胞移植后巩固治疗在有复发或进展风险的霍奇金淋巴瘤患者中的应用（AETHERA）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2015 May 9;385(9980):1853-62. doi: 10.1016/S0140-6736(15)60165-9. Epub 2015 Mar 19.
8
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.自体移植后复发/难治性霍奇金淋巴瘤中维布妥昔单抗治疗：荟萃分析与历史数据对比
Curr Med Res Opin. 2015 May;31(5):993-1001. doi: 10.1185/03007995.2015.1030378. Epub 2015 Apr 9.
9
Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?本妥昔单抗维迪西妥单抗在霍奇金淋巴瘤患者的治疗管理中处于什么位置？
Curr Hematol Malig Rep. 2012 Sep;7(3):179-85. doi: 10.1007/s11899-012-0126-1.
10
Targeted therapy in relapsed classical hodgkin lymphoma.复发经典型霍奇金淋巴瘤的靶向治疗。
J Natl Compr Canc Netw. 2013 Aug;11(8):968-76. doi: 10.6004/jnccn.2013.0117.
引用本文的文献
1
Advances in targeting histone deacetylase for treatment of solid tumors.靶向组蛋白去乙酰化酶治疗实体瘤的研究进展。
J Hematol Oncol. 2024 May 31;17(1):37. doi: 10.1186/s13045-024-01551-8.
2
Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors.蛋白酶体抑制剂与 NF-κB 通路在白血病和淋巴瘤中的相互作用：蛋白酶体抑制剂面临挑战的综合述评。
Cell Commun Signal. 2024 Feb 8;22(1):105. doi: 10.1186/s12964-023-01433-5.
3
Basal autophagy is pivotal for Hodgkin and Reed-Sternberg cells' survival and growth revealing a new strategy for Hodgkin lymphoma treatment.基础自噬对于霍奇金和里德-斯腾伯格细胞的存活和生长至关重要，这揭示了一种治疗霍奇金淋巴瘤的新策略。
Oncotarget. 2016 Jul 19;7(29):46579-46588. doi: 10.18632/oncotarget.10300.
4
Advancements in the delivery of epigenetic drugs.表观遗传药物递送方面的进展。
Expert Opin Drug Deliv. 2015;12(9):1501-12. doi: 10.1517/17425247.2015.1021678. Epub 2015 Mar 5.
5
Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.在接受多柔比星、博来霉素、长春花碱和达卡巴嗪联合化疗及放射治疗的早期经典型霍奇金淋巴瘤中，监测成像的效用非常低。
Cancer. 2015 Jun 15;121(12):1985-92. doi: 10.1002/cncr.29277. Epub 2015 Mar 4.
6
Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma.用Tenarad进行放射免疫治疗，Tenarad是一种靶向腱生蛋白-C胞外结构域A1的131I标记抗体片段，用于难治性霍奇金淋巴瘤患者。
Eur J Nucl Med Mol Imaging. 2014 May;41(5):867-77. doi: 10.1007/s00259-013-2658-6. Epub 2014 Jan 17.
7
Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant.经典型霍奇金淋巴瘤：适合移植的复发/难治性成年患者的淋巴瘤研究协会指南。
Haematologica. 2013 Aug;98(8):1185-95. doi: 10.3324/haematol.2012.072090.
8
Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.霍奇金淋巴瘤中特征性的 mTOR 活性为高危疾病提供了一个潜在的治疗靶点——一项联合组织微阵列、体外和体内研究。
BMC Cancer. 2013 May 22;13:250. doi: 10.1186/1471-2407-13-250.
9
Association of social network and social support with health-related quality of life and fatigue in long-term survivors of Hodgkin lymphoma.社会网络和社会支持与霍奇金淋巴瘤长期幸存者的健康相关生活质量和疲劳的关系。
Support Care Cancer. 2013 Aug;21(8):2153-9. doi: 10.1007/s00520-013-1775-x. Epub 2013 Mar 9.
10
Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols.检测经典型霍奇金淋巴瘤中 ABCC1 的表达与使用标准化疗方案治疗失败风险增加相关。
J Hematol Oncol. 2012 Aug 7;5:47. doi: 10.1186/1756-8722-5-47.
本文引用的文献
1
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.来那度胺治疗复发或难治性经典型霍奇金淋巴瘤的 2 期多中心研究。
Blood. 2011 Nov 10;118(19):5119-25. doi: 10.1182/blood-2011-07-362475. Epub 2011 Sep 21.
2
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.一项评估口服 mTOR 抑制剂依维莫司治疗复发性霍奇金淋巴瘤的 II 期临床试验。
Am J Hematol. 2010 May;85(5):320-4. doi: 10.1002/ajh.21664.
3
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.初步证据表明，pan 去乙酰化酶抑制剂 panobinostat（LBH589）对难治性霍奇金淋巴瘤有疗效。
Br J Haematol. 2009 Oct;147(1):97-101. doi: 10.1111/j.1365-2141.2009.07837.x. Epub 2009 Aug 5.
4
Cancer statistics, 2009.2009年癌症统计数据。
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.
5
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.一项关于SGN - 30（抗CD30单克隆抗体）用于霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤的II期研究。
Br J Haematol. 2009 Jul;146(2):171-9. doi: 10.1111/j.1365-2141.2009.07740.x. Epub 2009 May 19.
6
Frequent inactivation of A20 in B-cell lymphomas.A20在B细胞淋巴瘤中频繁失活。
Nature. 2009 Jun 4;459(7247):712-6. doi: 10.1038/nature07969. Epub 2009 May 3.
7
TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.TNFAIP3（A20）是霍奇金淋巴瘤和原发性纵隔B细胞淋巴瘤中的一种肿瘤抑制基因。
J Exp Med. 2009 May 11;206(5):981-9. doi: 10.1084/jem.20090528. Epub 2009 Apr 20.
8
Circulating clonotypic B cells in classic Hodgkin lymphoma.经典型霍奇金淋巴瘤中的循环克隆型B细胞。
Blood. 2009 Jun 4;113(23):5920-6. doi: 10.1182/blood-2008-11-189688. Epub 2009 Feb 2.
9
Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.服用你的PIK：磷脂酰肌醇3激酶抑制剂在临床中快速推进并迈向癌症治疗。
Mol Cancer Ther. 2009 Jan;8(1):1-9. doi: 10.1158/1535-7163.MCT-08-0801.
10
Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls.核因子-κB是癌症治疗的理想靶点吗？希望与困境。
Nat Rev Drug Discov. 2009 Jan;8(1):33-40. doi: 10.1038/nrd2781.
Zotero 插件